CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 92 enrolled
Drug / intervention
PCI-32765 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01478581
NCT01478581Phase 2Completed
CompareCT.gov

A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Pharmacyclics LLC.·interventional·Posted Nov 23, 2011·Updated Mar 10, 2020

In Brief

A Phase 2 clinical trial evaluating PCI-32765 and Dexamethasone for Multiple Myeloma. Completed, enrolled 92 participants across 11 sites.

Detailed Summary

The primary objective of this study is to determine the efficacy of PCI-32765, both as a single agent and in combination with dexamethasone, in subjects with relapsed or relapsed and refractory Multiple Myeloma (MM)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 23, 2011
Enrollment StartMar 1, 2012
Primary CompletionAug 1, 2018
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 14.6 years ago

Interventions

PCI-32765drug

Dexamethasonedrug